ImmuCell (ICCC) Projected to Release Quarterly Earnings on Thursday

ImmuCell (NASDAQ:ICCC) is projected to issue its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to announce earnings of $0.05 per share and revenue of $5.40 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:00 AM ET.

ImmuCell (NASDAQ:ICCC) last posted its earnings results on Thursday, August 13th. The biotechnology company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.15. ImmuCell had a return on equity of 2.69% and a net margin of 2.57%. The business had revenue of $7.19 million for the quarter, compared to analyst estimates of $5.40 million.

ImmuCell Stock Up 4.3%

ICCC opened at $10.22 on Tuesday. The stock’s fifty day simple moving average is $10.06 and its 200 day simple moving average is $8.95. ImmuCell has a 1-year low of $4.52 and a 1-year high of $12.10. The stock has a market cap of $92.80 million, a PE ratio of 129.62 and a beta of 0.61. The company has a current ratio of 4.75, a quick ratio of 2.71 and a debt-to-equity ratio of 0.22.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of ImmuCell from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, November 4th. One research analyst has rated the stock with a Hold rating. According to MarketBeat, the company presently has an average rating of “Hold”.

About ImmuCell

ImmuCell Corporation is a biotechnology and animal health company headquartered in Portland, Maine. The company develops, manufactures, and commercializes products designed to support the health and productivity of livestock, with a primary focus on cattle.

ImmuCell’s products include FirstStep Calf Health, an on-farm diagnostic test that helps dairy and beef producers assess whether newborn calves have received adequate passive immunity from colostrum. The company also develops antibody-based products intended to help prevent or manage common diseases affecting young livestock, including neonatal calf diarrhea.

Founded in 1987, ImmuCell serves the animal health market in the United States and has pursued regulatory approvals and commercial partnerships to expand the availability of its products.